First SPMS Patient Dosed With Foralumab Nasal Spray

First SPMS Patient Dosed With Foralumab Nasal Spray

295080

First SPMS Patient Dosed With Foralumab Nasal Spray

Foralumab, an investigational anti-CD3 antibody that is administered via a nasal spray, has been given for the first time to a person with secondary progressive multiple sclerosis (SPMS). It was administered under an Individual Patient Expanded Access Program, which earned approval from the U.S. Food and Drug Administration in April. It seeks to investigate the safety, tolerability, and changes in neurological behaviors after six months of foralumab use. The first patient was dosed at the Brigham…

You must be logged in to read/download the full post.